Wednesday 2 May | |
Direct Line Insurance Group | Q1 Results |
ConvaTec Group | Q1 Results |
Sage Group | Half Year Results |
Standard Chartered | Q1 Results (at 0515 BST) |
Paddy Power Betfair | Q1 Results |
Indivior | Q1 Results |
Howden Joinery Group | Trading Statement |
IWG | Trading Statement |
Inmarsat | Q1 Results |
Avon Rubber | Half Year Results |
Accsys Technology | Trading Statement |
Thursday 3 May | |
Glencore | Q1 Production |
Elektron Technologies | Full Year Results |
Equiniti Group | Trading Statement |
Centamin | Q1 Results |
James Fisher & Sons | Trading Statement |
IMI | Trading Statement |
esure Group | Q1 Results |
Lancashire Holdings | Q1 Results |
Trinity Mirror | Trading Statement |
Smith & Nephew | Trading Statement |
Apax Global Alpha | Q1 Results |
Wizz Air | April Traffic Statistics |
Friday 4 May | |
HSBC Holdings | Q1 Results (at 0500 BST) |
International Consolidated Airlines Group | Q1 Results |
InterContinental Hotels Group | Q1 Results |
Numis | Half Year Results |
Morgan Sindall | Trading Statement |
International Personal Finance | Trading Statement |
Millennium & Copthorne Hotels | Q1 Results |
Smurfit Kappa Group | Q1 Results |
Monday 7 May | |
no events scheduled | |
Tuesday 8 May | |
William Hill | Trading Statement |
Hiscox | Trading Statement |
Horizon Discovery Group | Full Year Results |
Faron Pharmaceuticals | Full Year Results |
Faron reveals details of next stage of bexmarilimab study
(Sharecast News) - Faron Pharmaceuticals announced on Monday that, following guidance from the US Food and Drug Administration (FDA), the initial indication for phase two advancement in the study investigating bexmarilimab in combination with standard of care, would focus on hypomethylating agents (HMAs)-refractory or relapsed myelodysplastic syndromes (MDS).
Read more